Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinical use of the co-formulation of insulin degludec and insulin aspart

Autor: A. Kumar, Ambrish Mithal, G. Gonzalez-Gálvez, Antonio Ceriello, M. Pinget, Sten Madsbad, León Litwak, T. Awata, R. Mehta, M A Tambascia, K. Kaku, Ambika Gopalakrishnan Unnikrishnan, Philip Home, R. Arechavaleta, Takahisa Hirose, Stephen C. Bain, Greg Fulcher, Jørgen S. Christiansen, J. Tibaldi

Publikováno v: Kumar, A, Awata, T, Bain, S C, Ceriello, A, Fulcher, G R, Unnikrishnan, A G, Arechavaleta, R, Gonzalez-Gálvez, G, Hirose, T, Home, P D, Kaku, K, Litwak, L, Madsbad, S, Pinget, M, Mehta, R, Mithal, A, Tambascia, M, Tibaldi, J & Christiansen, J S 2016, ' Clinical use of the co-formulation of insulin degludec and insulin aspart ', International Journal of Clinical Practice, vol. 70, no. 8, pp. 657-67 . https://doi.org/10.1111/ijcp.12821

SummaryAims To provide a review of the available data and practical use of insulin degludec with insulin aspart (IDegAsp). Premixed insulins provide basal and prandial glucose control; however, they have an intermediate-acting prandial insulin compon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::103655b9537f268293fd99fd6d41288d
https://cronfa.swan.ac.uk/Record/cronfa27110/Download/0027110-11042016104149.pdf

Why, when and how to initiate insulin therapy in patients with type 2 diabetes

Autor: J. Tibaldi, R. E. Rakel

Publikováno v: International Journal of Clinical Practice. 61:633-644

Type 2 diabetes is characterised by insulin resistance and progressive beta-cell deterioration. As beta-cell function declines, most patients with type 2 diabetes will require insulin therapy. Clinical studies show that tight control of blood glucose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fbb2c6865c54ee48d2a7f8025831d2fc
https://doi.org/10.1111/j.1742-1241.2007.01309.x

Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement

Autor: A G, Unnikrishnan, J, Tibaldi, M, Hadley-Brown, A J, Krentz, R, Ligthelm, T, Damci, J, Gumprecht, L, Gero, Y, Mu, I, Raz

Publikováno v: International Journal of Clinical Practice

Background: Basal insulin and premix insulin are commonly prescribed first-line insulin therapies for patients failing to maintain glycaemic control on oral therapy. When control on these insulins starts to drift, premix analogues, such as biphasic i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c277aa30fc7dfb7eff2445a964f7d65b
https://pubmed.ncbi.nlm.nih.gov/19780866